Thymogen Peptide

Thymogen is a synthetic dipeptide composed of L-glutamyl-L-tryptophan (Glu-Trp, or EW in single-letter code). With the molecular formula C₁₆H₁₉N₃O₅, a molecular weight of 333.34 g/mol, and CAS number 38101-59-6, Thymogen represents one of the simplest and most extensively characterized short peptide immunomodulators developed within the Russian peptide bioregulator research tradition. It was isolated and characterized in the late 1970s and early 1980s by Professor Vladimir Khavinson and colleagues at the Military Medical Academy in Leningrad (now St. Petersburg), as part of a systematic effort to identify the minimal active fragments contained within the thymus-derived polypeptide preparation known as Thymalin.

Thymogen occupies a defined position within the Khavinson “cytogen” family of short peptides, which also includes Vilon (Lys-Glu), Epithalon (Ala-Glu-Asp-Gly), and Livagen (Lys-Glu-Asp-Ala). Unlike Thymalin, which is a heterogeneous mixture of thymic polypeptides extracted from calf thymus tissue, Thymogen is a chemically defined, homogeneous synthetic molecule with reproducible batch-to-batch composition. This distinction has made Thymogen a preferred tool for mechanistic research into how ultra-short peptides influence immune cell differentiation, gene expression, and epigenetic regulation in preclinical models.

Since its initial description, Thymogen has been the subject of an extensive body of Russian-language and English-language literature, with studies spanning immunology, radiobiology, gerontology, and molecular biology. Research has explored its effects on T-lymphocyte differentiation, cytokine networks, neutrophil function, and its capacity to bind DNA and modulate gene expression in a sequence-specific manner. In preclinical models, Thymogen has been associated with restoration of immune parameters in states of secondary immunodeficiency, including those induced by aging, irradiation, cytostatic therapy, and surgical stress.

What distinguishes Thymogen from many other immunomodulatory peptides is its remarkable structural simplicity. As a dipeptide of only two amino acids, it represents a minimal pharmacophore for thymic peptide activity, providing researchers a tractable model system for investigating how very short peptides can nonetheless exert measurable effects on complex biological networks. This has made Thymogen particularly relevant to hypotheses proposed by Khavinson and collaborators regarding direct peptide-DNA interactions and epigenetic regulation as mechanisms underlying the activity of short bioregulator peptides. AminoCore Research supplies Thymogen as a lyophilized powder at ≥98% purity by HPLC, accompanied by a third-party certificate of analysis, exclusively for in vitro and preclinical research applications.

Thymogen (Glu-Trp) is proposed to act through several complementary mechanisms that collectively influence immune cell development, gene expression, and cellular signaling. Research suggests that its activity is not mediated by a single classical receptor but rather through multiple intersecting pathways characteristic of the Khavinson short peptide family.

T-Lymphocyte Differentiation and Maturation
The best-characterized activity of Thymogen involves its influence on T-cell maturation. In preclinical models, Thymogen has been associated with accelerated differentiation of immature thymocytes into functionally competent CD4+ and CD8+ T-lymphocytes. Studies in aged or immunocompromised animals have reported increased numbers of E-rosette-forming cells, enhanced expression of T-cell surface markers, and restoration of CD4/CD8 ratios toward values observed in healthy young animals. These effects appear consistent with a “thymomimetic” profile, in which Thymogen partially reproduces trophic signals normally provided by intact thymic tissue.

Cytokine Network Modulation
Thymogen has been reported to modulate the production of key immunoregulatory cytokines, including interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α). Rather than acting as a pure stimulator or suppressor, Thymogen appears to normalize cytokine output, increasing production in states of immune depression and moderating output in states of pathological activation. This bidirectional modulation is a hallmark of the Khavinson bioregulator concept.

Neutrophil and Innate Immune Effects
Research in preclinical models has documented effects on innate immune cells, including enhanced phagocytic activity of neutrophils and macrophages, improved chemotaxis, and increased microbicidal capacity. These findings have been observed particularly in models of secondary immunodeficiency induced by surgery, burns, or cytostatic therapy.

Peptide-DNA Interaction and Epigenetic Regulation
A distinctive hypothesis advanced by Khavinson and collaborators proposes that short peptides such as Thymogen can enter the cell nucleus and interact directly with DNA, particularly in AT-rich regions of gene promoters. Molecular modeling and spectroscopic studies suggest that Glu-Trp can form hydrogen bonds with specific nucleotide sequences, potentially influencing the transcription of genes involved in cell differentiation and proliferation. While this mechanism remains an area of active investigation and debate, it provides a conceptual framework for how a dipeptide might exert sequence-specific biological effects.

Antioxidant and Cytoprotective Signaling
Thymogen has also been associated with modulation of oxidative stress markers in preclinical models, including reductions in lipid peroxidation and increases in endogenous antioxidant enzyme activity. These effects may be secondary to its immunomodulatory actions or may reflect direct cytoprotective properties of the tryptophan residue.

Compared with thymic peptides such as Thymalin (a complex polypeptide mixture) or Thymosin alpha-1 (a defined 28-amino-acid peptide), Thymogen represents the minimal structural motif for thymomimetic activity, making it a valuable reference compound for structure-activity relationship studies within the short peptide bioregulator class.

Thymogen is a fully defined synthetic dipeptide belonging to the Khavinson family of short peptide bioregulators. Its minimal two-residue structure makes it one of the shortest bioactive peptides characterised in the thymic peptide class, and its physicochemical properties reflect a small, highly water-soluble amphoteric molecule.

The formula C₁₆H₁₉N₃O₅ reflects the combination of glutamic acid (C₅H₉NO₄) and tryptophan (C₁₁H₁₂N₂O₂) minus one water molecule from peptide bond formation. The indole side chain of tryptophan contributes UV absorbance at 280 nm (ε ≈ 5,500 M^-1cm^-1), which is commonly used for spectrophotometric quantification of Thymogen solutions. The compound is amphoteric, with the α-amino group of glutamate (pKa ~9.7), the α-carboxyl of tryptophan (pKa ~3.2), and the γ-carboxyl side chain of glutamate (pKa ~4.3) all ionisable across physiological pH ranges.

Because of its minimal size, Thymogen lacks the higher-order secondary structure of the parent Thymalin extract and functions as a flexible, extended peptide in solution. This structural simplicity is central to its research appeal: it provides a chemically defined, reproducible ligand for interrogating the bioregulator hypothesis without the batch-to-batch variability of tissue-derived extracts.

Proper storage is essential to maintain the chemical integrity and research reproducibility of Thymogen (Glu-Trp). Although the dipeptide is structurally simple compared to larger peptides such as Thymosin alpha-1 or Thymalin extract, the presence of the tryptophan residue introduces specific stability considerations that determine handling protocols.

Lyophilized Powder Storage

• Long-term storage: Store lyophilized Thymogen at -20°C or lower in the original sealed vial. Under these conditions, purity is expected to remain ≥98% for at least 24 months from the date of manufacture.
• Short-term storage: The sealed lyophilized vial may be kept at 2-8°C for up to several weeks without measurable degradation.
• Transit / room temperature: Brief exposure to ambient temperatures (up to 25°C) for 5-10 days during shipping does not significantly affect a properly sealed lyophilized dipeptide, as reflected in standard cold-chain-independent shipping practices for short peptides.
• Keep the vial desiccated and protected from light. The tryptophan indole ring is susceptible to photo-oxidation on prolonged UV exposure.

Reconstituted Solution Storage

• Once reconstituted in bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, store the solution at 2-8°C.
• Reconstituted Thymogen is stable for approximately 14-28 days at 2-8°C when protected from light. For longer storage of reconstituted material, aliquot and store at -20°C, avoiding repeated freeze-thaw cycles.
• Freeze-thaw tolerance: limit to ≤3 cycles; each cycle risks incremental loss of active peptide through aggregation or oxidation of the tryptophan side chain.

Compound-Specific Stability Notes

• Tryptophan photo-oxidation: Prolonged exposure to UV or intense visible light can generate N-formylkynurenine and kynurenine derivatives. Always store vials in the dark (amber vial, foil overwrap, or refrigerator interior).
• Oxidative degradation: While tryptophan is less susceptible to atmospheric oxygen than methionine or cysteine, dissolved oxygen in reconstitution solvents can slowly degrade the indole ring. Purging headspace with inert gas is recommended for long-term aqueous storage.
• pH sensitivity: Optimal stability is observed at slightly acidic to neutral pH (5.0-7.0). Strongly alkaline conditions accelerate peptide bond hydrolysis.
• Hygroscopicity: The lyophilized powder can absorb atmospheric moisture. Allow vials to equilibrate to room temperature before opening to prevent condensation on the powder cake.

All storage recommendations apply to research use only. A certificate of analysis (COA) confirming identity, purity, and mass is provided with each lot supplied by AminoCore Research.